Orgenesis enters collaboration agreement with Tel Aviv Sourasky Medical Center to establish point-of-care cell therapy center

Orgenesis (NASDAQ:ORGS) Inc. said it entered into a collaboration agreement with Tel Aviv Sourasky Medical Center to establish a point-of-care (POCare) cell therapy center at the Ichilov Hospital, a leading multidisciplinary healthcare institution in Israel.

The collaboration will initially focus on advancing the clinical development and validation of Orgenesis (NASDAQ:ORGS)’ CD19 CAR-T therapies, including CAR-T derived exosome products, utilizing Orgenesis’ proprietary T-cell culturing and point-of-care processes and systems, the global biotech company said in a statement.

Orgenesis and Tel Aviv Sourasky Medical Center also plan to deploy Orgenesis Mobile Processing Units and Labs (OMPULs) onsite to support joint research and validation activities for advanced cell and gene therapies they develop. OMPULs are multi-purpose, mobile, autonomous good manufacturing practice (GMP) facilities designed to significantly reduce the costs of advanced therapy production and accelerate the clinical development process at the point of care.

“This latest collaboration agreement also expands our POCare network capacity and provides further validation of the importance of our OMPULs,” said Vered Caplan, CEO of Orgenesis.

 “We remain focused on finding exceptional partners like the Tel Aviv Sourasky Medical Center to accelerate development of our broad portfolio of therapies, as well as deploy the OMPULs across our network of leading healthcare facilities and partner companies across the U.S., Europe, Asia, and the Middle East,” he added.

READ: Orgenesis leading the charge at an exciting time for cell therapy

Tel Aviv Sourasky Medical Center’s Deputy Director-General for Research, Development and Innovation, Prof Eli Sprecher said: “This collaboration, utilizing Orgenesis’ POCare platform, reflects our commitment to helping bring potential breakthrough cell therapies to market in a cost effective, high quality and scalable manner.”

Tel Aviv Sourasky Medical Center is the largest acute care facility in Israel, treating about 400,000 patients and hosting 1.8 million patient visits per year.

Story by ProactiveInvestors